Literature DB >> 25229402

Smad3/Nox4-mediated mitochondrial dysfunction plays a crucial role in puromycin aminonucleoside-induced podocyte damage.

Lixia Yu1, Yanbo Liu2, Yanfeng Wu3, Qifeng Liu1, Jianhua Feng1, Xiaoxia Gu1, Yan Xiong1, Qingfeng Fan4, Jianming Ye5.   

Abstract

Podocyte depletion due to apoptosis is the key hallmark of proteinuric kidney disease progression. Recently, several studies reported that mitochondrial (mt) dysfunction is involved in podocyte injury, while the underlying molecular mechanisms remain elusive. This study investigated the potential proximal signaling related to in vitro and in vivo mitochondrial dysfunction in a puromycin aminonucleoside (PA)-induced podocyte injury model. PA time- and dose-dependently resulted in cultured mouse podocyte damage, presenting with an increase of apoptotic cells and induction of activated caspase3/9. PA also caused mitochondrial damage and dysfunction based on the downregulation of the mtDNA level, decrease of transcriptional factors mtTfa and Nrf-1, decrease of CoxI, II and IV, and reduction of the oxygen consumption level and mitochondrial membrane potential level as well as excessive production of cellular ROS. Additionally, antioxidant MnSOD and catalase levels were decreased in mitochondrial fractions, and reduction of complex I and IV activity was also observed in PA-stimulated podocytes. Furthermore, an obvious translocation of p-Smad3 from the cytosol to nuclei and induction of mitochondrial Nox4 were detected following PA application. The PA-induced shift of cytochrome c was observed from mitochondria to the cytoplasm. Induction of Nox4 by PA administration was significantly repressed by Smad3-shRNA, while Nox4-shRNA showed no effect on PA-induced p-Smad3 activation. Notably, both Smad3 and Nox4 silencing significantly prevented the reduction of the mtDNA level, restored mitochondrial function, and decreased cellular apoptosis in PA-stimulated podocytes. A similar mitochondrial dysfunction was obtained in a PA-injected nephropathy rat, which was effectively inhibited by treatment with the antiproteinuric drug prednisone. In addition, Dab2 knockdown decreased albumin uptake and influx whereas it showed no effect on cellular apoptosis in PA-stimulated podocytes. In conclusion, our findings demonstrated that Smad3-Nox4 axis-mediated mitochondrial dysfunction is involved in PA-induced podocyte damage likely via increasing ROS generation and activating the cytochrome c-caspase9-caspase3 apoptotic signaling pathway. Dab2 may be required for the increased permeability of podocytes following injury.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mitochondrial dysfunction; NADPH oxidative (Nox4); Podocyte damage; Proteinuria; Puromycin aminonucleoside (PA); Smad3

Mesh:

Substances:

Year:  2014        PMID: 25229402     DOI: 10.1016/j.cellsig.2014.08.030

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  18 in total

1.  Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.

Authors:  Ahmed Bettaieb; Shinichiro Koike; Samah Chahed; Yi Zhao; Santana Bachaalany; Nader Hashoush; James Graham; Huma Fatima; Peter J Havel; Artiom Gruzdev; Darryl C Zeldin; Bruce D Hammock; Fawaz G Haj
Journal:  FEBS J       Date:  2017-05-29       Impact factor: 5.542

Review 2.  Nutrient sensing, signaling transduction, and autophagy in podocyte injury: implications for kidney disease.

Authors:  Dongqing Zha; Xiaoyan Wu
Journal:  J Nephrol       Date:  2022-06-15       Impact factor: 3.902

Review 3.  Sirtuin Family and Diabetic Kidney Disease.

Authors:  Che Bian; Huiwen Ren
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-14       Impact factor: 6.055

4.  Evidence of the Importance of Nox4 in Production of Hypertension in Dahl Salt-Sensitive Rats.

Authors:  Allen W Cowley; Chun Yang; Nadezhda N Zheleznova; Alexander Staruschenko; Theresa Kurth; Lisa Rein; Vikash Kumar; Katherine Sadovnikov; Alex Dayton; Matthew Hoffman; Robert P Ryan; Meredith M Skelton; Fahimeh Salehpour; Mahsa Ranji; Aron Geurts
Journal:  Hypertension       Date:  2015-12-07       Impact factor: 10.190

Review 5.  Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease.

Authors:  Yves Gorin; Fabien Wauquier
Journal:  Mol Cells       Date:  2015-03-31       Impact factor: 5.034

Review 6.  The podocyte power-plant disaster and its contribution to glomerulopathy.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-15       Impact factor: 5.555

Review 7.  Role of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An Update.

Authors:  Cheng Wan; Hua Su; Chun Zhang
Journal:  Oxid Med Cell Longev       Date:  2016-08-15       Impact factor: 6.543

8.  Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.

Authors:  Xiujin Shen; Hong Jiang; Meike Ying; Zhoutao Xie; Xiayu Li; Haibing Wang; Jie Zhao; Chuan Lin; Yucheng Wang; Shi Feng; Jia Shen; Chunhua Weng; Weiqiang Lin; Huiping Wang; Qin Zhou; Yan Bi; Meng Li; Lingyan Wang; Tongyu Zhu; Xiaoru Huang; Hui-Yao Lan; Jing Zhou; Jianghua Chen
Journal:  Sci Rep       Date:  2016-09-01       Impact factor: 4.379

9.  Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats.

Authors:  Yosuke Kawamorita; Takeshi Shiraishi; Yoshifuru Tamura; Takanori Kumagai; Shigeru Shibata; Yoshihide Fujigaki; Makoto Hosoyamada; Takahiko Nakagawa; Shunya Uchida
Journal:  Physiol Rep       Date:  2017-08

10.  Smad3 initiates oxidative stress and proteolysis that underlies diaphragm dysfunction during mechanical ventilation.

Authors:  Huibin Tang; Catherine L Kennedy; Myung Lee; Yang Gao; Hui Xia; Francesca Olguin; Danielle A Fraga; Kelsey Ayers; Sehoon Choi; Michael Kim; Amir Tehrani; Yasser A Sowb; Thomas A Rando; Joseph B Shrager
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.